U.S.

FDA approves first gene therapy for use in the U.S.

Today, the U.S. Food and Drug Administration made Kymriah available for patients under 25 to be treated with if they have a certain kind of acute lymphatic leukemia (a type of cancer where the body does not create normal lymphocytes) that is either in second or later relapse or is refractory. Kymriah is immunotherapy that uses patients’ own T-cells, which are genetically modified to kill leukemia and infused back into the patient.

This treatment has the potential to help thousands of young people that are suffering from leukemia in the status quo. The approval of this new gene therapy also opens new possibilities for the treatment of life-threatening illnesses such as cancer. However, there are possibly many serious side effects to the treatment, such as neurological problems; thus, the FDA has outlined strict requirements and guidelines for the utilization of Kymriah to ensure safe use.

Image: Steve Gschmeissner/Science Source

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s